everyone. morning, Good Jim. Thanks,
the results. Before on direct presentation Relations begin, website, summarizing fiscal from items I and the to to quarterly our our everyone year I'd like Investor key
the in and year-over-year driven Tech for $XX.X continued revenue fourth increased to FY thrombectomy. 'XX including strength Med NanoKnife platforms, Auryon, million, by Our quarter of our X.X%
light growth time. results plan. of initiatives QX strong very capacity growth against year's particularly continued for fact the with that prior our our at our execution the QX 'XX back of last we year-over-year, XX.X% pleased order a significantly year are year, exhibited strong as strategic reduced had the in FY over existing so improvement that QX of illustrate We Last the
a year-over-year growing X.X% FY Device quarter compared $XX.X was fourth of Med to million, Tech revenue was $XX.X while Med XX.X% 'XX. increase, million, the revenue
XX.X%. For and years X.X% two prior-year of our the of year a Through Med Device the first our our grown full XX.X% plan, platform Tech grew grew Med XXXX, our at period. has to three-year CAGR segment compared Med Tech the businesses
XX% For Tech comprised quarter, the platforms revenue. fiscal our our total fourth of Med
revenue to Med XXXX, For XX% for XXXX. XX% year fiscal our comprised platforms the of full Tech our total compared
the platform Our during $XX.X fourth million contributed to quarter, revenue Auryon XX% compared growing in year. last
Jim we business significant additional up of atherectomy addressable the are trajectory very are VTE indications that this opportunities the international will as well markets. space, in developing open and in mentioned, as pleased think with As additional we
revenue AlphaVac revenue, the X.X% over FXX for 'XX. which Both Mechanical fourth thrombectomy AlphaVac and versions million. are includes was of increased sales, FXX quarter the feedback. well positive and and of AngioVac receiving fourth quarter AlphaVac the performing FY physician $X.X
year $X.X prior XXXX, the revenue X.X% a sequentially in was third was For over revenue up but million the AngioVac million. $X.X decline AlphaVac full quarter. the the quarter, from of for representing year,
challenges we've address AngioVac the committed during to year, against and ongoing challenges Jim As saw in and are action these 'XX. meaningful to them mentioned, taken executing
of year For XXXX, AngioVac $XX.X decline X.X%. the was full revenue million, a
confident that our PE thrombectomy be product well Jim growth the significant and in the as as this introductions that We prioritize our a strategy, study. remain to mechanical initiatives, continue as platform, we APEX contributor will including such investments mentioned, will clinical to new
quarter XX% revenue during disposable the NanoKnife year-over-year. increased
grew NanoKnife XX.X%. For the XXXX, full disposables year of sales
well international that enrollment continue see is we're business in in to XXX% now announce pleased our complete. PRESERVE We very perform and in to U.S. this markets, both and
our the products in strength led fourth Med grew the In year-over-year, segment business. quarter, angiographic dialysis and Device X.X% by our
fourth the our million. $X.X at stood quarter, of end the of backlog As
X.X%, For target with Device year segment long-term of our Med X% X% the growth. full XXXX, our to grew in line
Moving down the income statement.
XX.X%, for fourth to basis a FY margin of the XXX of gross points year-ago the quarter period. compared was 'XX Our decrease
For to points gross of margin full 'XX, basis the XX.X%, year fiscal XXX a decrease year compared was XXXX.
each the of a Med of For fourth when margin Device basis compared points, points, last XXX the of was gross Tech fourth XX.X%, and year. gross Med decrease to margin decrease XXX was a XX.X%, quarter, quarter basis
basis Tech year, a each XX.X%, XXX the year the margins of Med gross again, 'XX. points, were to points, full a and Med full of compared Device For decrease XXX were when margins basis XX.X%, decrease
years. this a expansion higher-margin we become strategic our overall as gross the Tech As seen overall continues revenue mitigated dynamic, and the contemplates Med been margin has business of base. to that two our by we've discussed, segment pressures our larger over we've past however, portion And supply experienced disruptions chain have the inflationary model impact
significantly a year, and remained paydown performance of in segment, The ahead that When Med quarterly negatively corporate at AngioVac impacted looking approximately the IIA gross benefit provided year-over-year performance royalty of by and the the million The over margins of by hurdle productivity, $X this the the these in increased course capital international specifically than Act and offset the the were revenue of Tech positively impacted headwinds. partially the by margins but discussed Device growth. mix more placements. from the Med benefit overall margins. increased QX we was continued 'XX by increased created offsetting resulting FY inflationary CARES environment, shift was benefit
Turning to R&D.
of X% development million expenses compared a of sales or million FY sales and ago. research to $X.X quarter 'XX X.X% Our was the or during fourth year $X.X of
R&D product portfolio. development X.X% in drive expense or key $XX.X the compared Our for X.X% to disciplined growth platforms, $XX.X R&D previous million year. full includes Med and XXXX the year and for our will million sales across to our Tech clinical was spend of sales or of technology investment the in continue
anticipate this spend FY year, and to R&D proforma X% June that was completed 'XX X.X% BioSentry of FY sales. spend For to businesses in 'XX, of our in was of basis of accounting we a the on sales. XX% Dialysis divestiture R&D for target When
FY SG&A a of quarter for 'XX $XX.X to $XX.X sales expense year sales of the compared ago. representing or million million, XX.X% XX.X% of fourth was
SG&A the in of to For XXXX, million, sales was sales year of million, full 'XX. XX.X% representing representing XX.X% $XXX.X FY compared expense $XXX.X
XX% SG&A SG&A in accounting revenue. basis For FY FY was XX.X% on spend 'XX, spend of When 'XX divestiture, target XX% the proforma anticipate for sales. of a to we to
at BioSentry stated associated of and significant were the a we divestiture, was not businesses. time As of costs direct the the there that amount Dialysis with
a for As but a sales spend spending, result, 'XX as also in in sales and FY percent an include increase include SG&A of to expectations marketing. do respect G&A leverage our with
adjusted $X.X quarter fourth of $X.X the of adjusted of to FY earnings for $X.XX or of million income quarter in 'XX net net of fourth or compared $X.XX adjusted earnings an year. Our share adjusted was the million last per share per income
For share $X.XX loss share approximately loss per of or per $X.X million on the net compared to ago. net an or loss full a year adjusted basis of $X.X adjusted was million adjusted XXXX, breakeven year a
reimbursement share corresponding retention credit of our a benefit As FY FY $X.XX per expenses a Act, to related share of the 'XX certain adjusted CARES reminder, or benefit earnings under 'XX in in part per the included no $X.X our employee the million with as numbers.
included in income, our the fiscal that GAAP Device goodwill X, Med were May to of to on held-for-sale businesses XXXX, subsequent These net our XXst connection for as as with of divested in reported and XXXX. accounted our businesses. earnings release impairment as June divestiture segment morning, were end BioSentry a this our year related Dialysis
basis. quarter a in a goodwill GAAP impairment impairment XX, as on or we fiscal ended $X.XX the resulted per So result, of XXXX. The reported a a fourth $XX.X million during loss share May
fourth of in GAAP timing sale but recorded quarter gain larger fiscal our to 'XX, large 'XX, gain the is until assets be offsetting recorded of of then 'XX. is the GAAP of of 'XX. first be Due won't in on loss quarter quarter fiscal for FY in it our Result fourth loss the the FY a the FY will quarter first transaction, but a the the the
of fourth to quarter million quarter FY fourth 'XX compared Adjusted the million 'XX. EBITDA in $X.X the in $X.X FY was of
X.X%. to FY adjusted million over full representing the growth 'XX, 'XX, was in For million $XX.X year EBITDA year-over-year compared of $XX.X
equal $XX to cash at outstanding XX, compared delayed cash revolving May amounts 'XX, XXXX, to February evaluation Auryon fiscal $X.X to February additions in had facilities XXXX, the the and placement million of $XX.X million May cash, had under in is units equivalents million million we and credit million $XX.X and to $X.X XX, at operating divestiture, our of XX, and XX. at facility outstanding fourth million In expenditures which cash term the draw prior million. equivalents in $XX loan of XXXX. and generated under we capital At under $XX We these outstanding quarter had cash our
used our the to Subsequent we to the quarter-end, proceeds divestiture extinguish debt. from part of
currently As balances zero debt. a we significant have cash and result,
our throughout As cash building is year year. the the fiscal have to cash with fiscal of first always highest the fiscal during case, utilization the we quarter the expect of balances remainder
expect by period. we FY of the to in aggregate finish utilized the million to flow an over cash cash So two-year XXXX and positive to to having fiscal balances 'XX, $XX million $XX year $XX of with approaching million, the expect $XX million range of end be we
had and way, the FY end cash. million fiscal another in expect million In earnout tax expected said next $XX deal to for paid Auryon 'XX, the Auryon 'XX. million when million our transaction the we we costs, by final of and immediately a to accounting $X $XX of $X with the June, earnout, Now, after pay payment occur
So that bring 'XX. 'XX $XX million payments that of $XX-plus million down $XX FY in million to milestone
of 'XX to cash reflecting the cash to We for million million $XX to million $XX fiscal $X $XX operating end expect year of balances year. our with million, usage
flow the We execute strategic timing then QX on utilization have balances to throughout of payments toward that cash of and more generating our than year. exhibit we 'XX. our initiatives, we move cash sufficient given working QX with managing to Again, the as our will believe growing the end positive capital, cash FY
began we transformation a XXXX, of AngioDynamics. In
to early-stage to sale our Fluid laser. largest And the led Auryon PAD a to Management of the large investing in transformation began that an our can compete change markets. NAMIC proceeds to the step a startup, portfolio high-margin, We The which selling then, our buy of technologies by and transformation advantage platform first business Eximo the provide fundamentally higher-growth, Business. that time, Israeli was the at unique Medical, incorporate addressable total from third
strategic two our our initiatives internal expand treat reporting Med continued our mechanical business to and the into device, intermediate-risk AlphaVac cancer by Med in and investing Tech Device, use launch to for study our including APEX to PRESERVE using We've and for our clinical transformation PE segments, patients. NanoKnife study uses, R&D of in thrombectomy specific prostate
In July XX%. to of of Med for of CAGR to three-year Tech CAGR our XX%. our of segment plan, segment of two Through executing Med a XX% XXXX, that we articulated a years goal a has Tech three-year
In of company on sheet Tech objectives. businesses, focusing We've indicated the we active enhanced our BioSentry with Dialysis and our completed goal that divestiture year, which we be recapitalized Med the managers would strategic of portfolio our this our of our and June focus. balance
Gross margin the out market, COVID we've rebounded. pandemic, been which the tight expansion of has proved fully challenging. has Coming labor not impacted global by
Med makes addition, to In to and our us efficiencies. it pressures, businesses a our inflationary leaves very offering scale, ability drive under that Device limiting and wide contain us product susceptible
The a look of limitations next is and our to of manner, address medium our and the to in update on you actions operating capital-efficient phase the transformation short to in term. continuing enhancements to and margin plans our drive footprint structural scale we forward and
anticipate to range million be the Turning $X.XX. now the $XXX million, of be $X.XX adjusted share to year loss 'XX in of $XXX We expect will FY in per to range guidance. that revenue to and full we
direct margins and both while and significant share corporate assets $X.XX, to 'XX this line. cash when to the divested earnings transaction a proforma dilutive million at assets. means, As excluding of it a per the carry is cost, $XXX.X divested fiscal reminder, larger compares very to the of little proceeds, which provided recently clip year proforma loss revenue Those
XX% proforma 'XX in of of XX.X%. the expect to margin margin range to FY We gross be 'XX XX% FY compared to gross
of revenue range to growth XX% range expect FY X%. For XX% of we revenue to 'XX, Med Tech X% in in the and the Med Device growth
and Device Med of the the XX% gross XX% gross expect Med We in margins XX% range margins in XX%. range of Tech to to
I'll turn it With to Jim. that, back
